BioSpace News Archive

Drug Development

Ascendis Pharma Announces Completion of Target Enrollment in Phase III Trial of TransCon Growth Hormone for Pediatric Growth Hormone Deficiency

Top-line results anticipated in the first quarter of 2019.

January 4, 2018
·
5 min read
Drug Development

FDA Bestows Breakthrough Tag on Shire’s Maribavir

Maribavir is a Phase 3 investigational treatment for cytomegalovirus infection and disease in transplant patients resistant or refractory to prior therapy.

January 4, 2018
·
9 min read
Business

iTeos Therapeutics Regains Worldwide Rights to Clinical-Stage IDO1 Inhibitor

iTeos Therapeutics today announced that it has regained exclusive worldwide rights from Pfizer to develop and commercialise EOS200271, a highly selective, clinical-stage IDO1 inhibitor.

January 4, 2018
·
3 min read
Genetown

Hologic Inc. Delivers Notice That Holders of 2.00% Convertible Exchange Senior Notes Due 2042 are Eligible to Convert

Hologic announced today that it has notified holders of the 2.00% Convertible Exchange Senior Notes due 2042 issued March 5, 2012, and Wilmington Trust Company, the trustee, paying agent and conversion agent for the notes, that holders are eligible to convert the notes.

January 4, 2018
·
2 min read
Drug Development

SCYNEXIS Provides Corporate and SCY-078 Pipeline Update

SCYNEXIS today provided a corporate update, including recent pipeline developments and anticipated milestones in 2018, for its lead antifungal candidate, SCT-078.

January 4, 2018
·
10 min read
Business

Adesis Announces Joanne Johnson as Vice President of Business Development

Prior to joining Adesis, Dr. Johnson was Vice President of Business Development at Asymchem, Inc.

January 4, 2018
·
4 min read
Business

McKesson Corporation Fiscal 2018 Third Quarter Conference Call Scheduled for February 1, 2018

The company has scheduled a conference call for 8:00 AM Eastern Time (5:00 AM Pacific Time).

January 4, 2018
·
1 min read
Business

Onconova Therapeutics Announces Cooperative Research and Development Agreement for Rigosertib with the National Cancer Institute

Under the terms of the CRADA, the NCI will conduct research, including preclinical laboratory studies and a clinical trial, on rigosertib in pediatric cancer associated RASopathies.

January 4, 2018
·
7 min read
Biotech Bay

Atara Biotherapeutics Announces Pricing of Public Offering of Common Stock

The offering is expected to close on or about January 8, 2018, subject to customary closing conditions.

January 4, 2018
·
3 min read
Heptares Scientists Solve Structure of Complement C5a Receptor, an Important Drug Target for Inflammatory and Neurodegenerative Diseases, and Cancer

The findings, published in Nature today, reveal the location of a new allosteric binding site outside the transmembrane helical bundle and provide insights to the mechanisms by which small molecules interact with and modulate the receptor.

January 4, 2018
·
2 min read